 Shares of Rigel Pharmaceuticals Inc. RIGL, 1.86 soared 39.5 in premarket trading Friday, after the biotechnology company announced Food and Drug Administration approval of its Rezlidhia leukemia treatment. With trading volume of 5.2 million shares, the stock was the most active ahead of the open. 